Therapeutic potential of CD20 x CD3 bispecific antibodies

  • Post author:
  • Post category:uncategorized

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.